Jeune Aesthetics Announces Positive Clinical Phase I (PEARL-1 Study) Efficacy Results for KB301, an Investigational Gene-based Treatment Designed to Address the Underlying Biology of Aging Skin

Jeune Aesthetics, Inc. announced positive proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301, Jeune Aesthetics’ lead candidate for the treatment of aesthetic skin conditions. KB301 leverages Krystal’s proprietary gene delivery platform to restore protein production and rebuild the underlying ECM structure.